Up to 65% of well-differentiated and de-differentiated liposarcomas have a high rate of MDM2 amplification, while several other solid malignancies, including GBM, soft-tissue and bone sarcomas, gallbladder and duodenal adenocarcinoma, lung adenosquamous carcinoma, and ovarian carcinosarcoma, have a frequency of approximately 15% [28,45]. Here, MDM2 is linked to glioblastoma.